Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.

Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC.

Schizophr Bull. 2011 Jul;37(4):727-36. doi: 10.1093/schbul/sbp121. Epub 2009 Nov 21.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Psychiatr Serv. 2007 Apr;58(4):489-95.

4.

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T.

Med Care. 2002 Aug;40(8):630-9.

PMID:
12187177
5.

Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD.

J Clin Psychiatry. 2013 Dec;74(12):1249-55. doi: 10.4088/JCP.12m08331.

6.

A pilot study of barriers to medication adherence in schizophrenia.

Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G.

J Clin Psychiatry. 2004 Feb;65(2):211-6.

PMID:
15003075
7.
8.

Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.

Morrissette DA, Stahl SM.

CNS Spectr. 2012 Nov;17 Suppl 1:10-21. doi: 10.1017/S1092852912000739. Review.

PMID:
23462201
10.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
11.

Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial.

Fortney JC, Pyne JM, Kimbrell TA, Hudson TJ, Robinson DE, Schneider R, Moore WM, Custer PJ, Grubbs KM, Schnurr PP.

JAMA Psychiatry. 2015 Jan;72(1):58-67. doi: 10.1001/jamapsychiatry.2014.1575. Erratum in: JAMA Psychiatry. 2015 Jan;72(1):96.

PMID:
25409287
12.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

13.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
14.

Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.

Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T.

Schizophr Bull. 2004;30(2):255-64.

15.

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.

Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M.

Int J Geriatr Psychiatry. 2000 Jun;15(6):506-14.

PMID:
10861916
16.

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60. doi: 10.1016/j.pnpbp.2007.12.002. Epub 2007 Dec 14.

PMID:
18226436
17.

Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness.

Woltmann EM, Valenstein M, Welsh DE, Lee TA, Wolschon PA, Grabowski J, Reilly PA.

Psychiatr Serv. 2007 Jun;58(6):864-7.

PMID:
17535949
18.

Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?

Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M.

Schizophr Bull. 2010 Mar;36(2):428-35. doi: 10.1093/schbul/sbn106. Epub 2008 Aug 20.

19.

Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.

Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S.

J Clin Psychiatry. 2001 Jul;62(7):545-51.

PMID:
11488366
20.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk